TFOS DEWS III and Light-Based Therapy
The TFOS DEWS III Management and Therapy Report, published in the American Journal of Ophthalmology in 2025, is the leading international consensus on dry eye disease. Produced by the Tear Film and Ocular Surface Society, it consolidates the evidence published since DEWS II in 2017 and updates how the disease is defined, diagnosed and treated. Its recognition of low-level light therapy is the most significant external validation of Espansione's primary modality.
What DEWS III changed
Three shifts stand out. First, a sharper definition: dry eye is now explicitly a symptomatic disease and a subset of ocular surface disease, so signs without symptoms do not, by definition, constitute dry eye. Second, a simplified diagnostic pathway: screen with the OSDI-6, confirm with a single sign, and never skip ocular surface staining, replacing the inconsistent nine-test habit surveys had found. Third, and most consequential for treatment, a move from the evaporative-versus-aqueous split to a driver-based subclassification across three groups: tear film deficiencies, eyelid anomalies and ocular surface abnormalities.
How light therapy is positioned
DEWS III replaced staged management with a driver-led treatment matrix, matching each driver to treatments with a genuine evidence base. Within it, the report recognises low-level light therapy, the LM™ LLLT (PBM) modality delivered on eye-light®, as beneficial across all three driver groups: in the lipid and aqueous layers of the tear film, in eyelid abnormalities including meibomian gland dysfunction, and on the ocular surface where staining reveals damage. Few interventions span all three, which is why a single modality that does is unusually practical for the typical multi-driver patient.
What this recognition does and does not mean
Inclusion in DEWS III reflects an accumulating randomised evidence base, and it positions light therapy as an effective, evidence-based option across the driver groups. It does not, on its own, license blanket superiority claims; those rest only on the specific head-to-head trials. The report is also candid that the contraindication and precaution literature for both LLLT and IPL is not exhaustively defined, so clinical judgement and the device IFU remain the framework. Used within its cleared indications, LM™ LLLT fits exactly the way DEWS III asks clinicians to practise: diagnose simply, classify by driver, and treat the drivers found.
Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.